Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the company is issuing a US recall for all doses of NATPARA® (parathyroid hormone) for Injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg). This recall is being conducted after discussions with the FDA and is effec
WSOC
/cloudfront-us-east-1.images.arcpublishing.com/cmg/LH3JSJEF3VBLRJLJQESEAG34AM.png)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/INIPJDENXRDZJDZJH25FT7D76U.png)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/SWNKG6TR5ZDIFJHRE3MIO7Y6QE.jpeg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/TZXO4QLA7ZDEVNMPB3MVVI7ZJY.png)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/TZFNRJK3UZCNDLRYME4GGG22UA.png)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/WYAFD7APWJFFJEUFBECB4TXWEY.jpeg)